American Journal of Biology and Natural Sciences
https://biojournals.us/index.php/AJBNS
ISSN: 2997-7185

Recent Advances in Understanding the Relationship between the Human Gut Microbiome and Gastrointestinal Health

Ali Salah Jumaah
Department of Biology, College of Science, University of Basrah, Basrah, Iraq

Ali Almurtadha Ahmed Hasan
Department of Biology, College of Science, University of Basrah, Basrah, Iraq

Forqan Sameer Jasim
Department of Biology, College of Science, University of Basrah, Basrah, Iraq

Received: 2025, 10, Aug
Accepted: 2025, 09, Sep
Published: 2025, 08, Oct

Abstract: One of the key factors influencing gastrointestinal and systemic health in humans is the gut microbiota. It is made up of trillions of microorganisms that interact dynamically with the physiology of their hosts, such as bacteria, viruses, fungus, and archaea. These microbes are not passive commensals; rather, they actively support immunological control, food metabolism, mucosal barrier integrity, and inter-organ communication through the gut–liver and gut–brain axis. There is mounting evidence that the microbial fermentation of dietary fibers produces short-chain fatty acids (SCFAs), which are essential for preserving intestinal homeostasis and preventing inflammation, metabolic disorders, and cancer. On the other hand, a variety of gastrointestinal disorders, such as inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), celiac disease, colorectal cancer, and extra-intestinal conditions like obesity, non-alcoholic fatty liver disease, and type 2 diabetes, have been linked to dysbiosis, or disruption of the gut microbial community.

Recent research on the dynamics and makeup of the gut microbiota, its roles in gastrointestinal disorders, and its mechanisms of action in health are summarized in this overview. We also examine new therapeutic approaches, such as fecal microbiota transplantation (FMT), tailored probiotics, precision nutrition, and probiotics and prebiotics. Lastly, we highlight the potential of microbiome-based therapies in personalized medicine while talking about current issues and potential future research avenues.

1. Introduction

Over the past 20 years, the idea of the gut microbiota has changed in biomedical research. In the past, gut microbes were thought to be mostly unimportant or even dangerous. Due to its significant influence on host metabolism, immunology, and disease susceptibility, the microbiome is now more widely acknowledged as a "virtual organ" (Parada Venegas et al., 2019). The taxonomic and functional diversity of gut bacteria has been mapped with previously unheard-of resolution thanks to advancements in sequencing methods, especially 16S rRNA and shotgun metagenomics. According to this research, the variation in microbiome composition between individuals is not random but rather the result of intricate interactions between lifestyle, environment, nutrition, and genetics. Significantly, a rising number of gastrointestinal and systemic illnesses are linked to changes in the structure and function of the microbiome, which are collectively referred to as dysbiosis (Song et al., 2020).

2. Composition and Dynamics of the Gut Microbiome

Beginning with maternal transmission at birth, the gut microbiota is formed early in life. In contrast to cesarean-delivered newborns, who are colonized by skin-associated bacteria including Staphylococcus and Corynebacterium, vaginally delivered infants receive germs similar to the maternal vaginal microbiota, which is dominated by Lactobacillus and Prevotella (Tan et al., 2014). The presence of human milk oligosaccharides during breastfeeding further influences microbial colonization, promoting Bifidobacterium.

The microbiome is extremely dynamic and responsive to dietary cues throughout life. While Western diets heavy in fat and processed sugars encourage Firmicutes/Bacteroidetes imbalance and pro-inflammatory microorganisms, diets strong in plant fibers and resistant starches boost the abundance of beneficial SCFA-producing taxa like Faecalibacterium prausnitzii. Microbial diversity and resilience can be diminished by antibiotic exposure, which can result in significant and occasionally irreversible alterations. Additionally, cultural and geographic factors have a role;

people in rural areas tend to have more varied microbiomes than people in metropolitan areas.

3. Mechanisms Linking the Microbiome to Gastrointestinal Health

3.1 Metabolic Functions

SCFAs, especially acetate, propionate, and butyrate, are produced by the microbial fermentation of indigestible carbohydrates. These metabolites affect systemic energy metabolism, modify immunological signaling, control epithelial barrier function, and supply energy to colonocytes (Tan et al., 2014).

3.2 Barrier Integrity

One important protective mechanism is the intestinal barrier. By improving tight junction proteins like occludins and claudins, SCFAs lower permeability and stop "leaky gut." Specifically, butyrate has direct anti-inflammatory properties and promotes the synthesis of mucus (Parada Venegas et al., 2019).

3.3 Immune Modulation

Microbial products influence adaptive immunity via interacting with innate immune receptors, such as Toll-like receptors (TLRs). By encouraging the development of regulatory T cells (Tregs), SCFAs reduce pro-inflammatory reactions. On the other hand, dysbiosis tilts immunity in favor of persistent inflammation.

3.4 The Gut–Brain and Gut–Liver Axes

Through signaling molecules, neurotransmitters, and microbial metabolites, the gut microbiome affects organs that are located far away. Microbes in the gut-brain axis control behavior, stress reactions, and serotonin synthesis. Hepatic lipid and glucose control is influenced by the microbiota's metabolism of bile acids through the gut-liver axis.

4. Dysbiosis and Gastrointestinal Disorders

4.1 Inflammatory Bowel Disease (IBD)

Reduced microbial diversity, decreased SCFA generation, and an overrepresentation of pathobionts such Escherichia coli are characteristics of Crohn's disease and ulcerative colitis. Although findings are still inconsistent, probiotics and FMT have demonstrated promise in causing remission (Derwa et al., 2017).

4.2 Irritable Bowel Syndrome (IBS)

Changes in fermentation and microbial imbalance are associated with IBS. Diets low in FODMAPs reduce fermentable substrates for bacteria that produce gas, which helps to reduce symptoms. FMT is still being investigated despite its inconsistent outcomes.

4.3 Celiac Disease

According to new research, dysbiosis may make gluten-induced inflammation worse in people who are genetically prone. In patients with celiac disease, there has been an increase in Enterobacteriaceae and a decrease in Bifidobacterium.

4.4 Colorectal Cancer

By preventing cancer and encouraging apoptosis, microbial metabolites—butyrate in particular—display protective properties. However, the development of tumors has been linked to pathogenic species such Fusobacterium nucleatum (Song et al., 2020).

4.5 Extra-Intestinal Conditions

Reduced microbial diversity and changed SCFA profiles are associated with type 2 diabetes and obesity. Increased gut permeability and ethanol-producing bacteria are linked to non-alcoholic fatty liver disease (NAFLD), which causes inflammation in the liver.

5. Therapeutic Strategies Targeting the Microbiome

- Probiotics: Although strain-specific effects must be taken into account, live microorganisms like Lactobacillus and Bifidobacterium strains can modify gut ecology.
- Prebiotics: Beneficial taxa are selectively stimulated by inulin and fructo-oligosaccharides, which are non-digestible fibers.
- Synbiotics: Probiotic and prebiotic combinations increase their synergistic benefits.
- Fecal Microbiota Transplantation (FMT): Under clinical assessment for IBD, IBS, and even metabolic diseases, FMT is quite beneficial for recurrent Clostridium difficile infections.
- Faecalibacterium prausnitzii and Akkermansia muciniphila are two novel prospects for next-generation probiotics and postbiotics. Microbial-derived metabolites, or postbiotics, are becoming more popular as safer substitutes.
- Precision Nutrition: As customized treatment approaches, nutritional therapies based on microbiome profiling are becoming more and more popular.

6. Emerging Technologies

Comprehensive understanding of microbiome function is made possible by developments in metagenomics, metabolomics, and metatranscriptomics. Predicting illness risk and treatment results is made possible by integration with machine learning and systems biology. Microbiome outcomes are being incorporated into clinical trials more often, opening the door for evidence-based treatments.

7. Challenges and Future Directions

Key challenges include:

- proving causation in disease-microbiome relationships as opposed to correlation.
- standardization of pipelines for analysis, sequencing, and sampling.
- addressing the differences between people in how their microbiomes react to treatments.
- FMT and engineered probiotics: ethical and regulatory implications.

Long-term longitudinal investigations, the creation of microbiome biomarkers for early illness diagnosis, and the incorporation of microbiome data into frameworks for customized treatment must be the main areas of future research.

8. Conclusion

Nowadays, the gut microbiota is seen as an organ-like system that influences both systemic and gastrointestinal health rather than as a passive passenger. One notable mediator of host-microbe symbiosis is SCFA. Numerous gastrointestinal and extra-intestinal illnesses are linked to dysbiosis, and treatments that target the microbiome have great potential. Personalized microbiome-based treatment will soon be possible thanks to ongoing developments in sequencing, systems biology, and clinical translation.

References (APA)

1. Derwa, Y., Gracie, D. J., Hamlin, P. J., & Ford, A. C. (2017). Systematic review with meta-analysis: The efficacy of probiotics, prebiotics, synbiotics and antibiotics in inflammatory bowel disease. Alimentary Pharmacology & Therapeutics, 46(4), 389–400. https://doi.org/10.1111/apt.14203

2. Parada Venegas, D., De la Fuente, M. K., Landskron, G., González, M. J., Quera, R., Dijkstra, G., Harmsen, H. J. M., Faber, K. N., & Hermoso, M. A. (2019). Short-chain fatty acids (SCFAs)-mediated gut epithelial and immune regulation and its relevance for inflammatory bowel diseases. Frontiers in Immunology, 10, 277. https://doi.org/10.3389/fimmu.2019.00277

3. Song, M., Chan, A. T., & Sun, J. (2020). Influence of the gut microbiome, diet, and environment on risk of colorectal cancer. Gastroenterology, 158(2), 322–340. https://doi.org/10.1053/j.gastro.2019.06.048
4. Sun, J., Kato, I., & Dipaola, R. S. (2024). Oral microbiome dysbiosis and gastrointestinal diseases: A narrative review. BMC Microbiology, 24, Article 49. https://doi.org/10.1186/s12866-024-02956-7
5. Tan, J., McKenzie, C., Potamitis, M., Thorburn, A. N., Mackay, C. R., & Macia, L. (2014). The role of short-chain fatty acids in health and disease. Advances in Immunology, 121, 91–119. https://doi.org/10.1016/B978-0-12-800100-4.00003-